Conclusively, the study suggests that Nogo-A targeted therapy might represent a safe and effective alternative to VEGF treatment in terms of promoting vascular repair without the risk of blood brain barrier disruption following cerebral ischemia. The gene discussed is VEGFA; the disease is Cerebral ischemia.